阿尼卡療法 ANIK 深 滬
等待開盤 12-26 09:30:00 美东时间
9.48
+0.090
+0.96%
華盛通- 最 高9.55
- 今 開9.465
- 成交量 9.31万股
- 最 低 9.44
- 昨 收 9.39
- 總市值 1.37亿
- 52周最高 18.37
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.8701
- 委 比 -27.54%
- 總股本 1442.12万
- 歷史最高 75.715
- 量 比 0.45
- 振 幅 1.17%
- 歷史最低 5.24
- 每 手 1
- 風險率 3.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Anika Therapeutics Q3 Adj. EPS $0.04 Beats $(0.27) Estimate, Sales $27.800M Inline
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.27) by 114.81 percent. This is a 116 percent increase over losses of $(0.25) per share from
11-05 20:17
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
Anika Therapeutics submitted the final module of its Hyalofast PMA to the FDA on October 31, 2025. The PMA includes 24-month FastTRACK Phase III clinical trial data and additional analyses. While the trial did not meet its pre-specified co-primary endpoints, Hyalofast demonstrated statistically significant improvements in key secondary endpoints, including KOOS Sports and Recreation, Quality of Life, and Total KOOS. Post-hoc analyses also showed ...
11-05 12:00
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. announced its third quarter 2025 financial results will be released on November 7, 2025, before the market opens. Senior executives will host a conference call at 8:30 a.m. ET that day. U.S. participants can dial 800-267-6316 with conference ID 5120265, or access the webcast via the company’s website. A replay will be available for two weeks. ANI specializes in rare disease treatments, generics, and brands, aiming to imp...
10-24 10:50
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
ANI Pharmaceuticals announced that results from the NEW DAY clinical trial of ILUVIEN for diabetic macular edema (DME) will be presented in a late-breaking oral presentation at the American Academy of Ophthalmology (AAO) 2025 Meeting. The presentation, titled "A Randomized, Active-Controlled Trial of Fluocinolone Acetonide 0.19mg Intravitreal Implant for Diabetic Macular Edema: The NEW DAY Study," will be delivered by Victor H. Gonzalez, MD, duri...
10-16 10:50
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 price target.
09-23 23:01
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
ANI Pharmaceuticals announced that its CEO, Nikhil Lalwani, and executive team will present at two upcoming investor conferences: the H.C. Wainwright Global Investment Conference on September 8 and the Morgan Stanley Global Healthcare Conference on September 9. Both events will be webcast live and available on the company's website for 90 days. ANI is a biopharmaceutical company focused on innovative therapeutics and sustainable growth through it...
08-25 20:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
07-31 01:07
